PPTA Statements

Wall Street Journal: Letter to the Editor

Dear Editor,

The article published May 3, “Researchers Explore Using Common Blood-Plasma Treatment to Fight Coronavirus,” calls necessary attention to the importance of intravenous immunoglobulin, IVIG, as a lifesaving therapy for people living with a range of serious, genetic, and chronic conditions. Increased use of IVIG as an untested treatment against COVID-19 risks limiting its availability for those patients whose lives rely on regular access to it. For many of these conditions, IVIG remains the only known treatment.

Continue reading

  • Created on .

PPTA Encourages Plasma Donation

President Trump made an appeal for plasma donation a few days ago and is echoing what people with serious, genetic, life-threatening diseases already know plasma donors save lives! Most people had not given much thought to plasma before the recent COVID-19 pandemic. Now, they are learning that plasma from a patient who has recovered from COVID-19 could be used to make therapies to treat others who are sick with the disease and could eventually be used to safeguard health care workers.

Continue reading

  • Created on .

PPTA Reacts to Huffington Post Article

An article published on April 15 by The Huffington Post details a plasma donor’s experience in light of health precautions caused by the spread of COVID-19. The Plasma Protein Therapeutics Association (PPTA), our members, and our patient stakeholder partners all agree, as do authorities across the United States and European Union, that plasma donors and plasma donation center staff are essential parts of our expansive health care infrastructure, especially during these difficult times.

Continue reading

  • Created on .

PPTA Statement on FDA Guidance Documents

PPTA is aware of the guidance documents released by the U.S. Food and Drug Administration on April 2 regarding Source plasma donor eligibility and is currently evaluating them. Our focus remains, as it has for nearly three decades, on patient and donor safety, and the safety of therapies derived from plasma.

  • Created on .

PPTA Responds to The Guardian Article

An article published March 25 by Stefanie Dodt and Samuel Gilbert in The Guardian continues the authors’ intentional maligning of plasma donors along the U.S.-Mexico border and perpetuates a divisive misrepresentation of the reality of border life between the United States and Mexico. The Plasma Protein Therapeutics Association (PPTA) and its member companies are grateful for every plasma donor, each of whom directly contributes to saving and improving the lives of people facing serious, inherited, and life-threatening diseases.

Continue reading

  • Created on .

Letter to CMS to Allow Home Infusion COVID

Dear Administrator Verma,

I am writing to ask for your consideration as the Centers for Medicare and Medicaid Services explores avenues to protect vulnerable patient populations during the COVID-19 pandemic. The Plasma Protein Therapeutics Association (PPTA) is the standard setting and global advocacy organization that represents plasma donation centers and manufacturers of plasma protein therapies. Our membership accounts for approximately 80% of plasma therapies in the United States. These therapies treat individuals with rare, chronic, and life-threatening conditions, such as immune deficiencies, certain neurological diseases, alpha-1 antitrypsin deficiency, and bleeding disorders.

Continue reading

  • Created on .

A Note to European Plasma Donors on the Spread of Coronavirus

At this time of global concern regarding spread of the novel coronavirus, PPTA wants to thank the millions of committed plasma donors who make lifesaving medicines for rare disease patients a reality and to remind them that donor safety continues to be a top priority for PPTA and its member companies. 

We also want current and potential new donors to know that:

  • plasma donation continues to be a safe process,
  • there have been no blood-borne transmissions of the coronavirus, and
  • the need for plasma donations is just as great as ever!

Continue reading

  • Created on .

A Note to U.S. Plasma Donors on the Spread of Coronavirus

At this time of global concern regarding spread of the novel coronavirus, PPTA wants to thank the millions of committed plasma donors who make lifesaving medicines for rare disease patients a reality and to remind them that donor safety continues to be a top priority for PPTA and its member companies. 

Continue reading

  • Created on .

PPTA Statement on H.R. 3

On December 12, the U.S. House of Representatives passed H.R. 3, “The Lower Drug Costs Act,” sponsored by Energy & Commerce Chairman, Rep. Frank Pallone, D- NJ. This bill, known as Speaker Pelosi’s drug plan, would put at risk patients with rare diseases who rely on access to plasma protein therapies.

Continue reading

  • Created on .
Copyright © 2020 PPTA. All rights reserved. (202) 789-3100